|
2020 Conference Publication Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda StudySanchorawala, Vaishali, Palladini, Giovanni, Minnema, Monique C., Jaccard, Arnaud, Lee, Hans C., Gibbs, Simon D., Mollee, Peter, Venner, Christopher P., Lu, Jin, Schonland, Stefan, Gatt, Moshe, Suzuki, Kenshi, Kim, Kihyun, Cibeira, M. Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania T. M., Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Chauveau, Dominique, Gries, Katharine S., Fastenau, John, NamPhuong Tran, , Qin, Xiang, Vasey, Sandra Y., Tromp, Brenda, Weiss, Brendan M. ... Wechalekar, Ashutosh D. (2020). Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study. 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-139438 |
|
2020 Conference Publication A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphomaTobin, Joshua W.D., Hapgood, Greg, Gandhi, Maher K., Mollee, Peter, Ma, Ti, Crothers, Anna and Scuffham, Paul (2020). A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. Washington, DC USA: American Society of Hematology. doi: 10.1182/blood-2020-138590 |
|
2020 Conference Publication Management and outcomes of testicular lymphoma in the rituximab era at an Australian tertiary centreMurali, Aarya, Boyle, Stephen, Mollee, Peter and Hapgood, Greg (2020). Management and outcomes of testicular lymphoma in the rituximab era at an Australian tertiary centre. 62nd ASH Annual Meeting, Online, 5-8 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2020-138440 |
|
2020 Conference Publication The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukemiaMurali, Aarya, Cross, Donna and Mollee, Peter (2020). The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukemia. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. AMSTERDAM: American Society of Hematology. doi: 10.1182/blood-2020-140966 |
|
2020 Conference Publication The role of whole body STIR MRI in assessing first biochemical relapse in patients with myelomaRowland, James and Mollee, Peter (2020). The role of whole body STIR MRI in assessing first biochemical relapse in patients with myeloma. 62nd ASH Annual Meeting, Online, 5-8 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2020-139194 |
|
2020 Conference Publication Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from AndromedaComenzo, Raymond L., Kastritis, Efstathios, Palladini, Giovanni, Minnema, Monique C., Wechalekar, Ashutosh D., Jaccard, Arnaud, Sanchorawala, Vaishali, Lee, Hans C., Gibbs, Simon D., Mollee, Peter, Venner, Christopher P., Lu, Jin, Schonland, Stefan, Gatt, Moshe, Suzuki, Kenshi, Kim, Kihyun, Cibeira, M. Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania T. M., Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Chauveau, Dominique, Dimopoulos, Meletios A., NamPhuong Tran, , Qin, Xiang, Vasey, Sandra Y. ... Merlini, Giampaolo (2020). Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-137582 |
|
2020 Conference Publication Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late RelapseWeisel, Katja, Geils, George F., Karlin, Lionel, Mollee, Peter, Chung, Tae-Hoon, Min, Chang-Ki, Sunami, Kazutaka, Goldrick, Amanda, Fang, Belle, Fowler, Jessica and Mateos, Maria-Victoria (2020). Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse. 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-133908 |
|
2020 Conference Publication An individualised, supervised exercise program is safe and feasible for patients with multiple myeloma: The MyeEx StudyNicol, Jennifer L., Hill, Michelle M., Cunningham, Brent, Nunan, Elizabeth, Woodrow, Carmel, Keating, Eliza, Adlard, Kirsten, Smith, Michelle, Mollee, Peter, Weber, Nicholas, Nicol, Andrew J. and Skinner, Tina L. (2020). An individualised, supervised exercise program is safe and feasible for patients with multiple myeloma: The MyeEx Study. COSA's 47th Annual Scientific Meeting, Quality and Safety, Implementation Science, Cardio-Oncology, Virtual, 11–13 November 2020. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. doi: 10.1111/ajco.13499 |
|
2020 Journal Article Physical activity in people with multiple myeloma: associated factors and exercise program preferencesNicol, Jennifer L., Woodrow, Carmel, Burton, Nicola W., Mollee, Peter, Nicol, Andrew J., Hill, Michelle M. and Skinner, Tina L. (2020). Physical activity in people with multiple myeloma: associated factors and exercise program preferences. Journal of Clinical Medicine, 9 (10) 3277, 3277-11. doi: 10.3390/jcm9103277 |
|
2020 Journal Article Bortezomib, melphalan, and dexamethasone for light-chain amyloidosisKastritis, Efstathios, Leleu, Xavier, Arnulf, Bertrand, Zamagni, Elena, Cibeira, Maria Teresa, Kwok, Fiona, Mollee, Peter, Hajek, Roman, Moreau, Philippe, Jaccard, Arnaud, Schonland, Stefan O., Filshie, Robin, Nicolas-Virelizier, Emmanuelle, Augustson, Bradley, Mateos, Maria-Victoria, Wechalekar, Ashutosh, Hachulla, Eric, Milani, Paolo, Dimopoulos, Meletios A., Fermand, Jean-Paul, Foli, Andrea, Gavriatopoulou, Maria, Klersy, Catherine, Palumbo, Antonio, Sonneveld, Pieter, Erik Johnsen, Hans, Merlini, Giampaolo and Palladini, Giovanni (2020). Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. Journal of Clinical Oncology, 38 (28), 3252-3260. doi: 10.1200/JCO.20.01285 |
|
2020 Journal Article Catheter-associated bloodstream infections in adults with cancer: a prospective randomized controlled trialMollee, P., Okano, S., Abro, E., Looke, D., Kennedy, G., Harper, J., Clouston, J., Van Kuilenburg, R., Geary, A., Joubert, W., Eastgate, M. and Jones, M. (2020). Catheter-associated bloodstream infections in adults with cancer: a prospective randomized controlled trial. Journal of Hospital Infection, 106 (2), 335-342. doi: 10.1016/j.jhin.2020.07.021 |
|
2020 Journal Article HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patientsBurgess, M., Chen, U. C. E., Mapp, S., Blumenthal, A., Mollee, P., Gill, D. and Saunders, N. A. (2020). HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients. Oncogene, 39 (35), 5756-5767. doi: 10.1038/s41388-020-01394-w |
|
2020 Journal Article Identifying an obinutuzumab resistant subpopulation of monocyte-derived-macrophages from patients with CLLBurgess, Melinda, Chen, Yu Chen Enya, Mapp, Sally, Mollee, Peter, Gill, Devinder and Saunders, Nicholas A. (2020). Identifying an obinutuzumab resistant subpopulation of monocyte-derived-macrophages from patients with CLL. Leukemia and Lymphoma, 61 (11), 1-5. doi: 10.1080/10428194.2020.1775211 |
|
2020 Journal Article Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidanceWeinkove, Robert, McQuilten, Zoe K, Adler, Jonathan, Agar, Meera R, Blyth, Emily, Cheng, Allen C, Conyers, Rachel, Haeusler, Gabrielle M, Hardie, Claire, Jackson, Christopher, Lane, Steven W, Middlemiss, Tom, Mollee, Peter, Mulligan, Stephen P, Ritchie, David, Ruka, Myra, Solomon, Benjamin, Szer, Jeffrey, Thursky, Karin A, Wood, Erica M, Worth, Leon J, Yong, Michelle K, Slavin, Monica A and Teh, Benjamin W (2020). Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. Medical Journal of Australia, 212 (10) mja2.50607, 481-489. doi: 10.5694/mja2.50607 |
|
2020 Journal Article Bortezomib use and outcomes for the treatment of multiple myelomaLoke, Crystal, Mollee, Peter, McPherson, Ian, Walpole, Euan, Yue, Mimi, Mutsando, Howard, Wong, Phillip, Weston, Helen, Tomlinson, Ross and Hollingworth, Samantha (2020). Bortezomib use and outcomes for the treatment of multiple myeloma. Internal Medicine Journal, 50 (9) imj.14886, 1059-1066. doi: 10.1111/imj.14886 |
|
2020 Journal Article A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working GroupMaqbool, M. Gohar, Tam, Constantine S., Morison, Ian M., Simpson, David, Mollee, Peter, Schneider, Hans, Chan, Henry, Juneja, Surender, Harvey, Yasmin, Nath, Lakshmi, Hissaria, Pravin, Prince, H. Miles, Wordsworth, Helen, Opat, Stephen and Talaulikar, Dipti (2020). A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. Pathology, 52 (2), 167-178. doi: 10.1016/j.pathol.2019.11.002 |
|
2020 Journal Article Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: Probing the lipid metabolomeMohamed, Ahmed, Collins, Joel, Jiang, Hui, Molendijk, Jeffrey, Stoll, Thomas, Torta, Federico, Wenk, Markus R., Bird, Robert J., Marlton, Paula, Mollee, Peter, Markey, Kate A. and Hill, Michelle M. (2020). Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: Probing the lipid metabolome. PloS One, 15 (1) e0227455, e0227455. doi: 10.1371/journal.pone.0227455 |
|
2020 Conference Publication 99Tc-DPD Bone scintigraphy correlates with left ventricular wall thickness and global longitudinal strain in patients with ATTR wild type cardiac amyloidosisRobinson, J., Burrage, M., Ngai, S., Mackenzie, E., Duong, J., Mollee, P. and Korczyk, D. (2020). 99Tc-DPD Bone scintigraphy correlates with left ventricular wall thickness and global longitudinal strain in patients with ATTR wild type cardiac amyloidosis. 68th Cardiac Society of Australia and New Zealand Annual Scientific Meeting, the International Society for Heart Research Australasian Section Annual Scientific Meeting and the 14th Annual Australia and New Zealand Endovascular Therapies Meeting, Online, 11-13 December 2020. Chatswood, NSW Australia: Elsevier. doi: 10.1016/j.hlc.2020.09.069 |
|
2020 Conference Publication Changing picture of ATTR wild type cardiomyopathy in Australia – Queensland Amyloidosis Centre experienceKorczyk, D., Woodcroft-Brown, V., Maffey, M. and Mollee, P. (2020). Changing picture of ATTR wild type cardiomyopathy in Australia – Queensland Amyloidosis Centre experience. 68th Cardiac Society of Australia and New Zealand Annual Scientific Meeting, the International Society for Heart Research Australasian Section Annual Scientific Meeting and the 14th Annual Australia and New Zealand Endovascular Therapies Meeting, Online, 11-13 December 2020. Chatswood, NSW Australia: Elsevier. doi: 10.1016/j.hlc.2020.09.100 |
|
2019 Conference Publication Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose DexamethasoneKalff, Anna, Khong, Tiffany, Ramachandran, Malarmathy, Norton, Sam, Mitchell, Andrew, Reynolds, John, Quach, Hang, Ho, P. Joy, Horvath, Noemi, Mollee, Peter, Kennedy, Nola, Kemp, Roslyn and Spencer, Andrew (2019). Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose Dexamethasone. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando Fl, Dec 05-10, 2019. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2019-130154 |
